drugset / Trial / NCT06497543
Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic
Phase 2
Not yet recruiting
80 enrolled
Hunan Province Tumor Hospital
Second People's Hospital of Hunan · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This study aimed to evaluate the efficacy and safety of intrathecal pemetrexed for SCLC patients with refractory brain metastases or leptomeningeal metastasis.
Timeline
- Start
- 2024-10-01
- Primary completion
- 2025-10-31
- Completion
- 2026-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pemetrexed | Small molecule | 50 mg | Other |